LINC02650: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Target Name: LINC02650

NCBI ID: G105378397

LINC02650

Other Name(s): Long intergenic non-protein coding RNA 2650 | long intergenic non-protein coding RNA 2650

LINC02650: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

LINC02650 is a long intergenic non-protein-coding RNA (lncRNA) that has been identified using RNA sequencing (RNA-seq) studies. This RNA is different from traditional proteins in that it is not made by translation of messenger RNA (mRNA), but instead is produced by non-coding transcription. LINC02650 has been shown to play a role in various cellular processes, including cell growth, survival, and transcriptional regulation.

Drug Target Potential

The potential drug targeting of LINC02650 is based on its unique mechanism of regulation and its involvement in cellular processes that are often disrupted in diseases such as cancer, neurodegenerative diseases, and autoimmune disorders. LINC02650 has been shown to be involved in the regulation of cell cycle progression, apoptosis, and angiogenesis, which are all processes that are critical for the development and progression of these diseases.

One potential mechanism by which LINC02650 could be targeted as a drug is its role in the regulation of the cell cycle. LINC02650 has been shown to play a negative role in the regulation of the G1 phase of the cell cycle, which is the stage at which cells prepare for cell division. This is associated with the regulation of the cyclin D1 gene, which encodes the protein cyclin D1.

Additionally, LINC02650 has been shown to be involved in the regulation of the G2 phase of the cell cycle, which is the stage at which cells prepare for cell division again. This is associated with the regulation of the cyclin B2 gene, which encodes the protein cyclin B2.

The disruption of the cell cycle progression is a hallmark feature of cancer, and targeting LINC02650 as a drug could potentially inhibit the growth and survival of cancer cells. This is consistent with the current understanding of the role of LINC02650 in cancer progression, which is to promote the maintenance of the cell cycle and contribute to the development of a more malignant state.

Biomarker Potential

The second potential mechanism by which LINC02650 could be targeted as a drug is its role in the regulation of apoptosis, which is the process by which cells undergo programmed cell death. LINC02650 has been shown to play a positive role in the regulation of apoptosis, which is associated with the production of pro-apoptotic proteins.

The production of pro-apoptotic proteins is a hallmark feature of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. LINC02650 has been shown to be involved in the regulation of the production of these proteins, which could potentially contribute to the development and progression of these diseases.

Additionally, LINC02650 has been shown to play a positive role in the regulation of angiogenesis, which is the process by which new blood vessels are formed. This is associated with the production of angiogenic factors, which are promoting factors that contribute to the development of blood vessels.

The disruption of angiogenesis is a hallmark feature of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. LINC02650 has been shown to be involved in the regulation of the production of angiogenic factors, which could potentially contribute to the development and progression of these diseases.

Conclusion

In conclusion, LINC02650 is a long intergenic non-protein-coding RNA that has been shown to play a role in various cellular processes, including cell growth, survival, and transcriptional regulation. The potential drug targeting of LINC02650 is based on its unique mechanism of regulation and its involvement in

Protein Name: Long Intergenic Non-protein Coding RNA 2650

The "LINC02650 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02650 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets